Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrd2996 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microneedles as transdermal drug delivery system for enhancing skin disease treatment.
Acta Pharm Sin B
December 2024
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China.
Microneedles (MNs) serve as a revolutionary paradigm in transdermal drug delivery, heralding a viable resolution to the formidable barriers presented by the cutaneous interface. This review examines MNs as an advanced approach to enhancing dermatological pathology management. It explores the complex dermis structure and highlights the limitations of traditional transdermal methods, emphasizing MNs' advantage in bypassing the stratum corneum to deliver drugs directly to the subdermal matrix.
View Article and Find Full Text PDFDermatology in Student-Run Clinics in the United States: Scoping Review.
JMIR Dermatol
December 2024
Department of Dermatology, Lewis Katz School of Medicine, Temple University, 225 Market Street, Philadelphia, PA, 19106, United States, 1 215-482-7546.
Article Synopsis
- Student-run clinics (SRCs) for dermatology have potential to improve health equity in skin-related issues, and a comprehensive analysis of these clinics can help enhance their effectiveness.
- A scoping review was conducted to gather and analyze literature on dermatology SRCs in the U.S. by systematically searching databases and screening relevant studies.
- The review identified at least 19 dermatology SRCs, highlighting common skin conditions treated, such as atopic dermatitis, acne, and psoriasis, and examined various factors like clinic logistics and barriers to care.
Contemplating Novel W/O Emulsion Based Gel for Anti-Psoriatic Activity of Tofacitinib in Imiquimod-Induced Balb/C Mice Model.
AAPS PharmSciTech
December 2024
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India.
Article Synopsis
- Tyrosine kinase inhibitors like tofacitinib (TCB) are effective in treating psoriasis, and this study aims to enhance TCB's effectiveness while minimizing side effects through a new topical emulgel formulation.
- The emulgel was created by combining TCB with various ingredients, resulting in a formulation with ideal viscosity, firmness, and controlled release of the drug over 24 hours.
- The new TCB-emulgel showed significantly improved anti-psoriatic effects in a mouse model, reducing psoriasis severity scores and inflammation markers compared to existing treatments, supporting its potential for clinical use in managing psoriasis.
Safety and effectiveness of secukinumab subcutaneous injection in Japanese patients with psoriasis vulgaris and psoriatic arthritis: A post-marketing surveillance.
J Dermatol
January 2025
Biostatistics, Novartis Pharma K.K, Tokyo, Japan.
Article Synopsis
- Secukinumab is a human monoclonal antibody that targets interleukin-17A, used to treat psoriasis vulgaris and psoriatic arthritis in a study with 997 participants in Japan.
- The study found that most patients received the standard dose of 300 mg over an average of about 288 days, with some experiencing adverse events, but no new safety concerns were raised.
- Effectiveness was demonstrated by significant improvements in patient assessments over time, with sustained benefits observed up to week 52 of treatment.
Post-Marketing Safety of Ustekinumab Based on 14-Year Follow-Up in Danish National Patient Data.
Pharmacoepidemiol Drug Saf
December 2024
Department of Pediatrics and Adolescent Medicine, Danish National University Hospital "Rigshospitalet", Copenhagen, Denmark.
Article Synopsis
- This 14-year cohort study investigated the long-term safety of ustekinumab, a biologic treatment for psoriasis, using data from Danish national registers.
- The study compared safety outcomes like cancers and serious infections in ustekinumab users against patients receiving other systemic treatments, including non-biologics and various biologic therapies.
- Results showed that ustekinumab is generally safe, with no major safety concerns identified, and users were younger and had different gender distributions compared to users of other treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!